摘要
目的探讨硼替佐米联合地塞米松方案治疗多发性骨髓瘤(MM)的临床疗效。方法选取该院诊治的51例MM患者作为研究对象,按治疗方案分为两组,观察组31例采用硼替佐米联合地塞米松治疗,对照组20例接受长春新碱、吡柔比星、地塞米松和左旋苯丙氨酸氮芥(马法兰)治疗。比较两组患者临床疗效、不良反应等情况。结果观察组总有效率为80.65%(25/31),对照组总有效率65.00%(13/20)差异显著(P<0.05);观察组对初治病例有效率为86.36%(19/22),难治复发病例有效率为66.67%(6/9);对肾功能正常病例有效率为90.00%(18/20),对肾功能损害病例的有效率为63.64%(7/11)差异显著(P<0.05);观察组总不良反应发生率为51.61%,对照组为65.00%,差异显著(P<0.05)。结论硼替佐米联合地塞米松治疗MM有效率高,不良反应轻,对初治患者疗效最显著,值得推广应用。
Objective To investigate the efficacy and side effects of bortezomib combined with dexamethasone in the treatment of patients with multiple myeloma （ MM） .Methods 51 MM patients were divided into observation and control groups based on treatment plan . The patients in observation group （31 cases） were treated with bortezomib combined with dexamethasone and those in control group （20 ca-ses） were treated with vincristine ,pirarubicin,dexamethasone and melphalan .Efficacy and adverse reactions were observed between the two groups.Results The total efficiency in observation group and control group were 80.65% （25/31） and 65.00% （13/20）,respectively （P〈0.05）.In observation group,the total efficiency in newly diagnosed patients and relapsed /refractory patients were 86.36%（19/22） and 66.67%（6/9）,respectively.The effective rates in cases of normal renal function and in cases of renal damage were 90.00%（18/20） and 63.64% （7/11）,respectively.The differences were statistically significant （P〈0.05）.The incidence of adverse reactions in observation group and control group were 51.61%and 65.00%,respectively（P〈0.05）.Conclusions Bortezomib combined with dexamethasone has a high overall response rate especially for newly diagnosed patients .And the side effects are light .It is worthily recommended in clinical appli-cation.
出处
《中国老年学杂志》
CAS
CSCD
北大核心
2014年第22期6261-6263,共3页
Chinese Journal of Gerontology
基金
四川省卫生厅资助项目(No.100260)
